Abstract 501P
Background
Previous studies have proved that EGFR exon 20 insertion (EGFRex20ins) mutation present in about 1.8% of non-small cell lung cancer (NSCLC). 22% of EGFRex20ins are co-occurring with EGFR amplification. The aim of this study is to investigate the clinical characteristics and efficacy in Chinese NSCLC patients harboring EGFRex20ins and EGFR amplification.
Methods
A total of 1483 patients with advanced NSCLC were screened. All variants of EGFRex20ins and other oncogenic drivers were identified by next-generation sequencing (NGS).
Results
EGFRex20ins were found in 2.2% of patients and a total of 38 patients were included in clinical characteristics analysis. Various EGFRex20ins were identified, most commonly V769_D770dup (26.3%) and D770_N771dup (23.7%). Interestingly, co-occurring EGFR amplification was found in 39.5% of patients (15/38). In patients with EGFR amplification, the median age was 58 years (range, 38 to 75 years), and 66.7% were female. Most of them were never-smokers (86.7%) and had adenocarcinoma (93.3%). These clinical characteristics were not significantly different from those without EGFR amplification (P > 0.05). Except for patients with EGFR-sensitive mutations, a total of 25 patients who had used EGFR-tyrosine kinase inhibitors (TKIs) were included in the survival analysis. Although there were no statistically differences in two group, a tendency of prolonged median progression-free survival (mPFS) in patients without EGFR amplification was found (80.5 versus 30.0 days, P = 0.175).
Conclusions
EGFR amplification often co-occur with EGFRex20ins in Chinese NSCLC, and the ratio is higher than previous studies in Caucasian. Although there was no difference in clinical characteristics and efficacy between patients with and without EGFR amplification, a tendency of prolonged mPFS in patients without EGFR amplification was found. Future prospectively large-sample-size studies are needed to evaluate this finding.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Guangdong Lung Cancer Institute.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract